Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-α production and FOXP3 + Treg generation.
Cristina Benito-VillalvillaAndrés de la Rocha-MuñozJacobo López-AbenteAlexander EggelIván BottoliThomas SeverinMaximilian WoisetschlägerÓscar PalomaresPublished in: Allergy (2022)
The uncovered novel molecular mechanisms of ligelizumab to regulate functional properties of pDCs from atopic donors might have important clinical implications for anti-IgE treatments in different IgE-mediated diseases.